Context Therapeutics Inc. · NASDAQ:CNTX
Soleus Capital Master Fund, L.P. reported a 5.20% stake in Context Therapeutics Inc. (Schedule 13G)
Event Feb 2, 2026 · Filed Feb 3, 2026
Soleus Capital Master Fund, L.P. reported a 5.20% stake in Context Therapeutics Inc., 4,776,398 shares, as a passive investor on Feb 2, 2026. Filed Feb 3, 2026 (Schedule 13G).
- Stake
- 5.20%
- Shares
- 4,776,398
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 6 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Soleus Capital Master Fund, L.P. | 5.20% | 4,776,398 |
| Soleus Capital, LLC | 5.20% | 4,776,398 |
| Soleus Capital Group, LLC | 5.20% | 4,776,398 |
| Soleus Capital Management, L.P. | 5.20% | 4,776,398 |
| Soleus GP, LLC | 5.20% | 4,776,398 |
| Guy Levy | 5.20% | 4,776,398 |
Source
Related
- Context Therapeutics Inc.
- Soleus Capital Master Fund, L.P.
- Context Therapeutics Inc. shareholders
- Schedule 13G/A · Soleus Capital Master Fund, L.P. · May 8, 2026
- Schedule 13G/A · Mpm Bioimpact LLC · Aug 14, 2026
- Schedule 13G/A · Blue Owl Capital Holdings LP · Aug 12, 2026
- Schedule 13G/A · Octagon Capital Advisors LP · Jul 31, 2026
- Schedule 13G · BlackRock, Inc. · Jul 27, 2026
- Schedule 13G/A · Great Point Partners LLC · May 15, 2026